TBA 354

Drug Profile

TBA 354

Alternative Names: TBA-354

Latest Information Update: 08 Apr 2016

Price : $50

At a glance

  • Originator Global Alliance for TB Drug Development; University of Auckland
  • Developer Global Alliance for TB Drug Development
  • Class Antituberculars; Nitroimidazoles; Oxazines; Pyridines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 19 Nov 2015 Global Alliance for TB Drug Development plans a phase I trial in Healthy volunteers in USA (NCT02606214)
  • 01 Jan 2015 Phase-I clinical trials in Tuberculosis (In volunteers) in USA (PO)
  • 12 Sep 2012 Pharmacodynamics & pharmacokinetics data from preclinical studies in Tuberculosis presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top